Q1 2019 Medicure Inc Earnings Call Transcript
Welcome to the first quarter 2019 conference call. My name is Paulette, and I will be your operator for today's call. (Operator Instructions) Please note that this conference is being recorded.
I will now turn the call over to Dr. Friesen. You may begin.
Thanks, Paulette, and good morning to all on the call. We appreciate your interest and participation on today's call. Joining me is the CFO, James Kinley; and Vice President Commercial, Kevin Taylor.
The number of patients using AGGRASTAT continues to increase although modestly to now just at 65%, but with pricing pressures, the net income is lower for this quarter. The revenue for the quarter ended March 31, 2019, from AGGRASTAT was $4.8 million, which was lower than Q1 2018, which was $6.1 million.
We also experienced negative earnings, substantially because of the significant investment in the market push for both ZYPITAMAG and ReDS. The adjusted EBITDA for Q1 was $1.7 million compared to -- negative $1.7
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
